Trobix Bio follows the funding trail

Trobix Bio, an Israel-based developer of enhanced antibiotics spun out of Tel Aviv University research, has made its public debut with an undisclosed amount of funding from investors led by Chartered Opus, a subsidiary of investment group Chartered Investment Managers.
Other investors in the round were not disclosed.
Trobix Bio has been formed to develop virus-derived particles containing DNA to sensitise bacterial pathogens that have built up resistance to existing antibiotic medications.
The spinout has exclusive worldwide rights to develop the technology, and plans to target fields including animal health, food safety and consumer health, in addition to human therapeutics.
The company builds on research led by Udi Qimron, a professor in the Department of Clinical Microbiology and Immunology at Tel Aviv University’s Sackler Faculty of Medicine.
Qimron’s team were funded through early development by Technology Innovation Momentum Fund, the venture fund launched by TAU’s tech transfer office, Ramot, though it was unclear whether the support included equity investment.
Shlomo Nimrodi, chief executive of Ramot and general partner of Momentum Fund, said: “The investment by Chartered Opus investment group, is an acknowledgement to the value that the Momentum Fund brings to early-stage academic innovations.”